Unformatted text preview: Essay Focus 704 www.thelancet.com Vol 369 February 24, 2007 The appearance of raed drugs on pharmacists’ shelves only increases the need to attend to the myriad social sources of disparities in morbidity and mortality. Although to turn a profi t from fi ghting racial discrimination is diﬃ cult, eff ective medical care demands continued awareness of the complex social dimensions of diseases, such as hypertension and cancer. Conﬂ ict of interest statement I declare that I have no conﬂ ict of interest. References 1 Financial Times (London) , March 9, 2001: 16. 2 Cohn J N. The Vasodilator-Heart Failure Trials (V-HeFT): mechanistic data from the VA Cooperative Studies. Circulation 1993: 87 (suppl 6 ) : V 1–2. 3 Kahn J. How a drug becomes ‘ethnic’: law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics 2004; 4: 1–46. 4 NitroMed. Press Release: NitroMed receives FDA letter on BiDil NDA, a treatment for heart failure in black patients. March 8, 2001. 5 Food and Drug Administration. FDA approves BiDil heart failure drug for black patients. June 23, 2005: http://www.fda.gov/bbs/ topics/NEWS/2005/NEW01190.html (accessed Dec 4, 2006). 6 Kahn, J. Misreading race and genomics after BiDil. Nat Genet 2005; 37: 655–56. 7 Taylor AL, Ziesche S, Yancy C, et al, for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. dinitrate and hydralazine in blacks with heart failure....
View Full Document
This note was uploaded on 10/10/2010 for the course ENG 000121 taught by Professor Mcgrand during the Spring '10 term at Cornell.
- Spring '10